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Purpose or Objective: A substantial number of patients with 
painful spinal metastases experience no effect of palliative 
radiotherapy. Besides tumor-induced pain, mechanical spinal 
instability due to metastatic disease, could be associated 
with failed pain control following conventional radiotherapy. 
Early identification of patients who will not benefit from 
radiotherapy is important, since these patients might benefit 
more from a surgical approach. This study aims to 
prospectively investigate the relation between spinal 
instability, as defined by the Spinal Instability Neoplastic 
Score (SINS), and the pain response to conventional palliative 
radiotherapy in patients with symptomatic spinal metastases. 
 
Material and Methods: From two academic centers, data of 
155 patients with thoracic, lumbar or lumbosacral metastases 
was prospectively collected. In all patients, SINS was 
calculated by a spine surgeon, specialized in spine oncology 
and blinded for treatment outcome. Images from 
radiotherapy planning computed tomography (CT) scans were 
used. The highest SINS was recorded in case more than one 
lesion was irradiated. Patients who died within four weeks 
after radiotherapy (n=13, 8%) or had an otherwise unknown 
pain response (n=18, 12%) were excluded. Pain response, 
determined using the International Bone Metastases 
Consensus Working Party, was recorded between 4 to 8 weeks 
after treatment in 124 patients. Multivariable logistic 
regression analysis was used to estimate the association 
between SINS and pain response in patients with spinal 
metastases. 
 
Results: In total, 81 (65%) patients experienced a pain 
response. Of the patients who died within four weeks after 
radiotherapy (n=13), 6 patients had SINS of 7 or higher. 
Except for Karnofsky performance score, no significant 
differences in patients and disease characteristics were found 
between responders and non-responders within the cohort. 
Median SINS was not significantly different between 
responding and non-responding patients. In multivariate 
analysis, SINS was not associated with pain response 
(adjusted odds-radio 0.94; 95% confidence interval 0.81–1.10; 
p = 0.449) (Table). SINS improved the prediction of response 
in addition to other clinical variables only marginally: the 
area under the receiver operating curve improved from 0.68 
(0.60–0.79) to 0.70 (0.60–0.80) (Figure). 
 
 
 
Conclusion: In this study no significant relationship between 
mechanical spinal instability, as reflected by the SINS score, 
and pain response to conventional radiotherapy could be 
demonstrated. SINS was developed as a referral tool in 
patients with spinal metastases, and is not useful as a 
predictive tool for pain response. 
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Purpose or Objective: Bone metastases are frequently 
treated with radiotherapy (RT) for pain, which also may have 
a beneficial effect on bone density, and thus bone strength. 
So far, only one study (Koswig et al., Strahlenther Onkol, 
1999) compared single fraction (SF) and multiple fraction 
(MF) RT in terms of remineralization and found a larger 
response after MF RT. However, they only studied lytic 
lesions in mostly vertebrae. Although a pathological fracture 
results in major problems for mobility and self-care, femoral 
lesions have been studied limitedly for remineralization. 
Furthermore, little is known about the effect of RT on bone 
tissue surrounding the lesions. Therefore, the aim of this 
study was to determine the effect of SF and MF RT on bone 
density over time in proximal femora and in lytic, blastic and 
mixed lesions.  
 
Material and Methods: In this prospective cohort study, 42 
patients with 47 femora irradiated for 52 metastatic lesions 
were included from three RT centers in the Netherlands. All 
patients received SF (1x8Gy) or MF (5 or 6x4Gy) RT, according 
to Dutch clinical guidelines. Quantitative computed 
tomography (QCT) scans were obtained before RT and 4 and 
10 weeks after RT. MF patients additionally underwent QCT 
on the final day of RT (after 1 week). Mean bone densities 
were determined at each time point for each proximal femur 
and for each lesion (expanded by 6 mm to account for 
obscure edges). For proper comparison over time, proximal 
femora and lesions were registered using an automated, 
objective and accurate registration method. Linear mixed 
models were used for statistical analysis. 
 
Results: No significant differences in bone density were 
found between SF and MF RT over all time points (Figure 1A). 
Blastic, lytic and mixed lesions responded differently to RT 
over time (Figure 1B). No difference in bone density was 
found for lytic lesions, whereas bone density in mixed and 
blastic lesions increased up to 105% (SD 10%) and 121% (SD 
17%) after 10 weeks, respectively. Comparably, bone density 
of the proximal femora with blastic lesions increased to 109% 
(SD 10%), while proximal femora with lytic and mixed lesions 
showed no difference in bone density over time.  
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Figure 1: Bone densities (percentage relative to baseline 
QCT) of the lesions over time, average ± SD; (A) SF vs. MF RT; 
(B) each lesion type. Symbols indicate significant differences 
within lesions (*blastic, † mixed), or between lesion types at 
ten weeks (**). 
 
Conclusion: In general, 10 weeks after RT in patients with 
femoral metastases a significant increase in bone density was 
seen in blastic and mixed lesions, but not in lytic lesions. 
However, the subsequent effect of these changes on femoral 
bone strength remains unknown. Since higher total doses did 
not lead to significantly higher bone densities, the clinical 
relevance of MF over SF for stabilizing femoral bone with 
metastases can be questioned. 
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Purpose or Objective: Advanced primary and recurrent 
rectal cancers (RC) may cause significant pelvic morbidity 
including pain, dysfunction and hematochezia. Palliative 
pelvic radiotherapy (PPRT) is often used but symptomatic 
effects and toxicities are poorly documented and optimal 
treatment schedules remain undefined. Aims of this 
prospective multicenter phase-II study were to evaluate 
changes in symptom severity and explore quality of life (QOL) 
and toxicity after PPRT of RC using a common palliative 
radiotherapy regimen. 
 
Material and Methods: Patients with symptomatic pelvic RC 
(primary or recurrent) prescribed PPRT with 30-39 Gy in 3 Gy 
fractions were eligible. Treatment volume included primary 
tumor or recurrence and enlarged pelvic lymph nodes, if 
indicated. Subjects identified a target symptom (TS) as their 
principal pelvic complaint requiring palliation. Primary 
outcome was self-reported TS severity relative to baseline 12 
weeks after PPRT. Pelvic symptom burden including toxicity 
and QOL (EORTC QLQ C30) were assessed before, at the end 
of, and six and 12 weeks after PPRT. 
 
Results: From Q4/2009-Q3/2015, 51 patients were included 
at 8/9 Norwegian radiotherapy centers. Thirty-three patients 
were evaluable 12 weeks after PPRT, and 16 (31%) did not 
complete the study due to progressive cancer (n=6) and 
death (n=10). Albumin < 36 g/L (OR=1.31 (95% CI 1.11-1.54)) 
and age ≤ 79 yrs (OR=4.79 (95% CI 0.97 -23.65)) were 
independent predictors of study drop-out. Median delivered 
dose was 36 Gy (6–39). Pain (n=24), rectal dysfunction (n=16), 
and hematochezia (n=9) were the most common TS. 28/33 
(85%) evaluable patients reported that their TS had either 
resolved or improved 12 weeks after PPRT. 4/33 (12%) 
reported unchanged TS severity, while one patient had 
worsening TS severity at the 12-week follow-up. Forty-two of 
the 51 included patients (82%) reported complete resolution 
or improvement of the TS at at least one of the three follow-
up visits. Hematochezia responded most rapidly and 
consistently with all evaluable patients reporting 
improvement or resolution. The time course of pain and 
rectal dysfunction severity was variable. Twelve weeks after 
PPRT, 10/13 (77%) and 9/10 (90%) of evaluable patients who 
had identified TS pain and rectal dysfunction, respectively, 
reported improvement or resolution. Non-target pelvic 
symptom severity decreased during the study. Median global 
QOL scores remained stable at follow-up visits. There was no 
grade 4 toxicity reported. Median survival after PPRT was 9 
months (0-51). 
